Literature DB >> 19341846

Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.

Andrew M Kaunitz1, David J Portman, Howard Hait, Kathleen Z Reape.   

Abstract

BACKGROUND: A cross-study analysis of contraceptive clinical trials for two different 91-day oral contraceptive (OC) regimens was performed to examine the impact on bleeding patterns when supplementing the 7-day hormone-free interval with 10 mcg ethinyl estradiol (EE) daily. STUDY
DESIGN: Two separate 1-year Phase 3 clinical programs were conducted using similar study designs. The percentages of subjects reporting bleeding and spotting using electronic diaries for each 91-day cycle were compared.
RESULTS: Scheduled bleeding with the EE regimen was less than that reported with the regimen utilizing placebo during Days 85-91, with significant differences noted for all four 91-day cycles. Unscheduled bleeding decreased more quickly with the 91-day regimen containing low-dose EE in place of placebo, with significant differences noted during the third cycle.
CONCLUSIONS: This cross-study comparison suggests that the administration of low-dose estrogen in place of placebo in a 91-day extended regimen OC improves the bleeding profile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19341846     DOI: 10.1016/j.contraception.2008.11.011

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Depot medroxyprogesterone acetate use and periodontal health in 15- to 44-year-old US females.

Authors:  L Susan Taichman; Woosung Sohn; Giselle Kolenic; Maryfran Sowers
Journal:  J Periodontol       Date:  2012-02-06       Impact factor: 6.993

Review 2.  Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): A Review of Its Use as an Oral Contraceptive.

Authors:  Celeste B Burness
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

3.  Combined hormonal contraceptives for heavy menstrual bleeding.

Authors:  Anne Lethaby; Michelle R Wise; Maria Aj Weterings; Magdalena Bofill Rodriguez; Julie Brown
Journal:  Cochrane Database Syst Rev       Date:  2019-02-11

Review 4.  The creeping Pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?

Authors:  James Trussell; David Portman
Journal:  Contraception       Date:  2013-04-11       Impact factor: 3.375

5.  New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control.

Authors:  Anita Nelson
Journal:  Int J Womens Health       Date:  2010-08-09

6.  The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg.

Authors:  Sheila Krishnan; Jessica Kiley
Journal:  Int J Womens Health       Date:  2010-08-10

7.  Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.

Authors:  Rossella E Nappi; Anna Maria Paoletti; Annibale Volpe; Luca Chiovato; Brandon Howard; Herman Weiss; Nancy Ricciotti
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-06-13       Impact factor: 1.848

8.  Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval.

Authors:  Rossella E Nappi; Paloma Lobo Abascal; Jennifer Hsieh; Marie-Christine Micheletti
Journal:  Int J Womens Health       Date:  2017-10-05

Review 9.  Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.

Authors:  Rossella E Nappi; Andrew M Kaunitz; Johannes Bitzer
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-11-17       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.